Sr. No.	Received from	Pending at the end of last month	Received	Resolved*	Total Pending #	Pending complaints >3months	Average Resolution time^ (in days)
1	Directly from Investors	0	0	0	0	0	0
2	SEBI (SCORES)	0	0	0	0	0	0
3	Other Sources (if any)	0	0	0	0	0	0
	Grand Total	0	0	0	0	0	0

Sr. No.

Received from

Pending at the end of last month

Received

Resolved*

Total Pending #

Pending complaints >3months

Average Resolution time^ (in days)

Directly from Investors

SEBI (SCORES)

Other Sources (if any)

Grand Total

Sr. No.	Month	Carried forward from previous month	Received	Resolved*	Pending#
1	Jun, 2026	0	0	0	0
2	Jul, 2026	0	0	0	0
3	Aug, 2026	0	0	0	0
	Grand Total	0	0	0	0

Sr. No.

Month

Carried forward from previous month

Received

Resolved*

Pending#

Jun, 2026

Jul, 2026

Aug, 2026

Grand Total

Sr. No.	Fin. Year	Received	Resolved*
1	2022-23	1	1
2	2023-24	0	0
3	2024-25	0	0
4	2025-26	1	1
	Grand Total	2	2

Sr. No.

Fin. Year

Carried forward from previous year

Received

Resolved*

Pending#

2022-23

2023-24

2024-25

2025-26

Grand Total

Top Pharma Companies in India by Market Cap

BSE Sensex 75550.42 1090.89 (1.47%)

Filter

Top Pharma Companies in India as on Nov-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

Expand company details	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)	More company information
121	Unichem Laboratories Ltd.	Q V PT	3,404 Small Cap	494 (2.18%)	11.17	1.24	12.26	24.44	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
122	Kovai Medical Center & Hospital Ltd.	Q V PT	6,356 Small Cap	5,734.45 (-1.27%)	24.8	4.58	18.09	25.97	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
123	Innova Captab Ltd.	Q V PT	5,900 Small Cap	1,023.90 (-0.70%)	37.75	5.2	31.75	26.73	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
124	Natco Pharma Ltd.	Q V+ PT	15,350 Small Cap	784.75 (0.29%)	13.41	1.45	14.72	28.08	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
125	Vimta Labs Ltd.	Q V+ PT	2,167 Small Cap	488.30 (0.71%)	26.97	4.41	14.27	28.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
126	Wanbury Ltd.	Q V+ PT	664 Small Cap	190.10 (0.18%)	15.44	9.89	10.29	30.27	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
127	Lupin Ltd.	Q V PT	91,870 Mid Cap	2,027.70 (0.93%)	16.62	3.86	13.02	32.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
128	Kwality Pharmaceuticals Ltd.	Q V+ PT	3,604 Small Cap	3,511.15 (1.08%)	44.47	10.11	13.94	34.90	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
129	Neuland Laboratories Ltd.	Q V+ PT	25,276 Small Cap	19,550.15 (-0.77%)	50.78	12.51	16.64	37.55	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
130	Syncom Formulations (India) Ltd.	Q V+ PT	1,810 Small Cap	19.35 (0.52%)	21.16	4.11	21.49	39.14	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
131	Sai Life Sciences Ltd.	Q V+ PT	33,139 Small Cap	1,550 (-0.62%)	91.61	12.98	23.61	39.96	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
132	Rainbow Childrens Medicare Ltd.	Q V PT	12,366 Small Cap	1,230.55 (1.07%)	42.32	7.21	21.24	43.99	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
133	Yatharth Hospital & Trauma Care Services Ltd.	Q V PT	8,942 Small Cap	940.65 (1.36%)	49.36	4.9	39.48	45.83	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
134	Rubicon Research Ltd.	Q V+ PT	26,650 Small Cap	1,669.90 (3.73%)	92.47	19.85	41.00	54.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
135	Kilitch Drugs (India) Ltd.	Q V PT	703 Small Cap	206.15 (2.56%)	23.38	2.5	28.00	58.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
136	Acutaas Chemicals Ltd.	Q V+ PT	32,770 Small Cap	4,000.20 (-0.06%)	74.62	17.64	31.50	70.35	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
137	Global Health Ltd.	Q V PT	34,122 Small Cap	1,315.65 (3.67%)	61.35	8.3	24.97	76.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
138	Artemis Medicare Services Ltd.	Q V PT	4,626 Small Cap	281.55 (-3.64%)	40.32	5.02	21.50	83.35	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
139	Max Healthcare Institute Ltd.	Q V PT	83,706 Mid Cap	900 (4.65%)	60.63	7.39	27.27	155.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Narayana Hrudayalay.	1,840.30	7.01%
Advanced Enzyme Tech	279.60	6.33%
Indegene	622.10	5.86%
Themis Medicare	99.84	5.09%
Max Healthcare Inst.	900	4.65%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Sigachi Industries	25.02	-5.23%
Morepen Laboratories	108.05	-4.97%
Concord Biotech	1,188	-4.60%
Bliss GVS Pharma	623	-3.92%
Artemis MedicareServ	281.55	-3.64%

News about Top Pharma Companies in India

Nov, 2026

RainbowChildrenS Med - Quaterly Results

A fair growth of 19.22% in the revenue at Rs. 4869.91 millions was reported in the September 2026 quarter as compared to Rs. 4084.96 millions during year-ago period.A meek growth of 2.63% was reported for the quarter ended September 2026 to Rs. 750.93 millions from Rs. 731.67 millions.Operating Profit saw a handsome growth to 1595.88 millions from 1488.91 millions in the quarter ended September 2026.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202609	202509	% Var	202609	202509	% Var	202603	202503	% Var
Sales	4869.91	4084.96	19.22	8975.38	7432.44	20.76	15456.60	14545.06	6.27
Other Income	80.92	81.73	-0.99	208.49	274.58	-24.07	434.54	489.49	-11.23
PBIDT	1595.88	1488.91	7.18	2870.04	2676.97	7.21	5433.11	5234.23	3.80
Interest	199.14	173.09	15.05	391.63	347.02	12.86	713.96	695.94	2.59
PBDT	1396.74	1315.82	6.15	2478.41	2329.95	6.37	4703.76	4538.29	3.65
Depreciation	398.09	331.82	19.97	774.35	657.75	17.73	1362.61	1317.48	3.43
PBT	998.65	984.00	1.49	1704.06	1672.20	1.91	3341.15	3220.81	3.74
TAX	247.72	252.33	-1.83	426.07	423.33	0.65	840.99	844.98	-0.47
Deferred Tax	-57.47	-27.87	106.21	-68.71	-22.06	211.47	-73.38	-31.54	132.66
PAT	750.93	731.67	2.63	1277.99	1248.87	2.33	2500.16	2375.83	5.23
Equity	1015.66	1015.59	0.01	1015.66	1015.59	0.01	1015.59	1015.52	0.01
PBIDTM(%)	32.77	36.45	-10.09	31.98	36.02	-11.22	35.15	35.99	-2.32

Oct, 2026

Artemis Medicare Services informs about newspaper publication

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Artemis Medicare Services has enclosed the copy of un-audited financial results for the quarter and half year ended September 30, 2026, published in the following newspapers on October 31, 2026: The Financial Express (English National Daily Newspaper- all editions); The Jansatta (Hindi National Daily Newspaper- Delhi edition). The aforesaid results are also accessible on the Company’s website at https://www.artemishospitals.com/investors.

The above information is a part of company’s filings submitted to BSE.

Oct, 2026

Vimta Labs - Quaterly Results

A fair growth of 9.95% in the revenue at Rs. 1119.83 millions was reported in the September 2026 quarter as compared to Rs. 1018.48 millions during year-ago period.A meek growth of 3.48% was reported for the quarter ended September 2026 to Rs. 206.14 millions from Rs. 199.20 millions.Operating profit surged to 407.78 millions from the corresponding previous quarter of 368.88 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202609	202509	% Var	202609	202509	% Var	202603	202503	% Var
Sales	1119.83	1018.48	9.95	2210.57	1994.12	10.85	4072.90	3439.82	18.40
Other Income	29.04	26.58	9.26	67.16	44.07	52.39	89.89	42.40	112.00
PBIDT	407.78	368.88	10.55	819.01	723.27	13.24	1505.08	1261.89	19.27
Interest	3.85	3.74	2.94	6.22	6.89	-9.72	11.67	19.00	-38.58
PBDT	403.93	365.14	10.62	812.79	716.38	13.46	1477.25	1242.89	18.86
Depreciation	128.68	102.40	25.66	254.16	201.02	26.44	437.72	352.89	24.04
PBT	275.25	262.74	4.76	558.63	515.36	8.40	1039.53	890.00	16.80
TAX	69.11	63.54	8.77	142.07	127.22	11.67	264.41	222.45	18.86
Deferred Tax	1.58	-3.17	-149.84	16.02	-7.23	-321.58	-1.07	12.66	-108.45
PAT	206.14	199.20	3.48	416.56	388.14	7.32	775.12	667.55	16.11
Equity	89.40	89.08	0.36	89.40	89.08	0.36	89.34	44.47	100.90
PBIDTM(%)	36.41	36.22	0.54	37.05	36.27	2.15	36.95	36.68	0.73

Oct, 2026

Max Healthcare Inst. - Quaterly Results

The company witnessed a 14.30% growth in the revenue at Rs. 8419.70 millions for the quarter ended September 2026 as compared to Rs. 7366.20 millions during the year-ago period.Profit for the quarter ended September 2026 grew by 4.93% to Rs. 1683.30 millions from Rs. 1604.20 millions.Operating profit surged to 2786.40 millions from the corresponding previous quarter of 2611.00 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202609	202509	% Var	202609	202509	% Var	202603	202503	% Var
Sales	8419.70	7366.20	14.30	16248.90	14306.40	13.58	28744.50	26636.00	7.92
Other Income	491.10	474.30	3.54	1412.10	1272.80	10.94	3019.50	3665.40	-17.62
PBIDT	2786.40	2611.00	6.72	5532.20	5286.60	4.65	11225.30	11999.30	-6.45
Interest	137.20	86.70	58.25	257.90	179.20	43.92	398.70	483.90	-17.61
PBDT	2649.20	2524.30	4.95	5274.30	5107.40	3.27	10670.20	10779.10	-1.01
Depreciation	387.70	367.70	5.44	753.70	722.00	4.39	1429.00	1311.90	8.93
PBT	2261.50	2156.60	4.86	4520.60	4385.40	3.08	9241.20	9467.20	-2.39
TAX	578.20	552.40	4.67	1161.30	1120.90	3.60	2075.10	2456.50	-15.53
Deferred Tax	-28.30	50.80	-155.71	-17.10	77.10	-122.18	196.70	482.90	-59.27
PAT	1683.30	1604.20	4.93	3359.30	3264.50	2.90	7166.10	7010.70	2.22
Equity	9733.10	9722.40	0.11	9733.10	9722.40	0.11	9731.30	9721.40	0.10
PBIDTM(%)	33.09	35.45	-6.64	34.05	36.95	-7.86	39.05	45.05	-13.31

Oct, 2026

Max Healthcare Institute reports 16% fall in Q2 consolidated net profit

The total consolidated income of the company has increased by 20.37% at Rs 2,610.11 crore for Q2FY27

Oct, 2026

Vimta Labs informs about unaudited financial results

Vimta Labs has enclosed unaudited Financial Results as per Regulation 33 of the SEBI (LODR) Regulations, 2015 for the 02nd Quarter and Half Year ended 30th September 2026 along with Limited Review Report. The said Financial Results were duly reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company, at their respective meetings held today. Further to earlier intimation dated 6th May 2026 regarding the proposed incorporation of a wholly owned subsidiary in the USA, the Board of Directors of the Company, at its meeting held today, took note of the incorporation of Vimta Labs LLC as a wholly owned subsidiary of the Company. The meeting of the Board of Directors of the Company commenced at 10:30 AM and concluded at 01:00 PM.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Indoco Remedies Ltd.	1,923 Crore
2	Piramal Pharma Ltd.	31,826 Crore
3	Sigachi Industries Ltd.	1,009 Crore
4	Solara Active Pharma Sciences Ltd.	3,055 Crore
5	Themis Medicare Ltd.	875 Crore
6	Hikal Ltd.	2,601 Crore
7	Suraksha Diagnostic Ltd.	1,653 Crore
8	Biocon Ltd.	57,365 Crore
9	Cohance Lifesciences Ltd.	17,005 Crore
10	3B Blackbio Dx Ltd.	1,113 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	25,731	54,384	33.68	10.51	23.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,598	1,76,306	83.01	9.60	33.08	29.04
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,390	65,137	36.23	5.94	12.08	27.89
Lupin Ltd. (M)	Somewhat Good	2,028	91,870	16.62	3.86	9.20	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,426	43,891	34.76	9.03	23.33	25.35

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	2,380	1,29,243	147
Sai Life Sciences Ltd. (S)	Somewhat Good	1,550	33,139	69.37
Gland Pharma Ltd. (M)	Very Good	3,069	51,112	61.94
Aurobindo Pharma Ltd. (M)	Very Good	1,668	96,537	52.18
Ipca Laboratories Ltd. (M)	Very Good	1,966	48,907	49.58
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Somewhat Good	1,550	33,139	91.61	12.98	47.25	23.61
Mankind Pharma Ltd. (M)	Very Good	2,511	1,02,797	45.84	5.85	24.28	18.10
Ajanta Pharma Ltd. (M)	Very Good	3,426	43,891	34.76	9.03	23.33	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,239	1,24,089	27.50	4.60	15.32	13.52
Gland Pharma Ltd. (M)	Very Good	3,069	51,112	45.28	4.81	23.17	13.18

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Sai Life Sciences Ltd. (S)	Somewhat Good	1,550	33,139	91.61	12.98	47.25	39.96
Lupin Ltd. (M)	Somewhat Good	2,028	91,870	16.62	3.86	9.20	32.37
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,390	65,137	36.23	5.94	12.08	22.19
Abbott India Ltd. (M)	Very Good	25,731	54,384	33.68	10.51	23.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,357	1,12,699	40.25	2.90	18.79	15.75

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Current Complaints

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the month.

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the year.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

RainbowChildrenS Med - Quaterly Results

Artemis Medicare Services informs about newspaper publication

Vimta Labs - Quaterly Results

Max Healthcare Inst. - Quaterly Results

Max Healthcare Institute reports 16% fall in Q2 consolidated net profit

Vimta Labs informs about unaudited financial results

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?